The addition of tislelizumab-jsgr (Tevimbra) to induction chemotherapy and concurrent chemoradiotherapy (CRT) boasted higher composite complete response (cCR) rates, which translated to improved survival vs the historical control of concurrent…
Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC
